| Document |
Document Title |
|
WO/2000/043350A1 |
Crystal polymorphism of 2-[4-[2-[[1s,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methyl ethyl]amino]ethyl]phenoxy]acetic acid which has potent $g(b)¿2? adrenergic receptor stimulating and $g(b)¿3?-adrenergic receptor stimulating effects, is us...
|
|
WO/2000/043345A1 |
The invention relates to an improved method for the industrial-scale production of L-phenylephrine hydrochloride 3 by asymmetric hydrogenation as key step and a special series of subsequent steps. According to the invention [Rh(COD)Cl]¿...
|
|
WO1999066944A9 |
Disclosed are novel multi-binding compounds (agents) which bind cellular receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such cellular receptors thereby modulating the biological proce...
|
|
WO/2000/043347A1 |
The invention concerns a method for making aqueous solutions of unsaturated quaternary ammonium salts of formula (I) by reacting, in the presence of water, N,N-dimethylaminoethyl acrylate with a quaternizing agent of formula (II): R - Cl...
|
|
WO/2000/043346A1 |
The invention concerns a method for making aqueous solutions of unsaturated quaternary ammonium salts of formula (I) by reacting, in the presence of water, N,N-dimethylaminoethyl acrylate with a quaternizing agent of formula (II): R-Cl. ...
|
|
WO/2000/043348A1 |
The invention concerns a method for making an aqueous solution of unsaturated quaternary ammonium salts of formula (I), by reacting, in the presence of water, N,N-dimethylaminoethyl acrylate with a quaternizing agent of formula (II):R-Cl...
|
|
WO/2000/040529A1 |
The invention relates to the use of compounds of formula (I): wherein X is -C(O)-, -C(S)-, -C=NOH, or -CH(R?7¿)- wherein R?7¿ is hydrogen, hydroxy, C¿1-7?alkoxy, -OR?8¿ or -NR?8¿R?9¿ (wherein R?8¿ is a group -Y?1¿R?10¿ (wherein ...
|
|
WO/2000/040950A1 |
This invention relates to a method for monitoring a chemical reaction of pharmaceutical relevance, comprising the steps of: consecutively obtaining Raman spectrum samples of a solution of chemical constituents contained within a reaction...
|
|
WO1999064035A9 |
Disclosed are multibinding compounds which are beta 2-adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system...
|
|
WO/2000/039071A1 |
An efficient process for stereoselectively producing L-erythro-(1R,2S)-2-amino-1-phenylpropan-1-ol from L-(R)-phenylacetylcarbinol, which comprises reductively aminating L-(R)-phenylacetylcarbinol with a primary aralkylamine under cataly...
|
|
WO/2000/039073A1 |
The invention is directed to a process for stereoselective chemical synthesis which comprises reacting a nucleophilic agent and a chiral quaternary azetidinum salt (QAS) substrate of formula (I), to produce a compound of formula (II).
|
|
WO/2000/039241A1 |
A compound of general formula (I), (II), or (III): wherein each of R¿1? through R¿20? are independently selected from straight or branched chain, substituted or unsubstituted C¿1?-C¿22? alkyl or alkenyl groups, wherein said alkyl or ...
|
|
WO/2000/039072A1 |
A method for preparing a compound of formula (IXa) from a compound of formula (VIIa), and preparation of intermediates useful in the method.
|
|
WO/2000/037425A1 |
Disclosed is a method for producing N-methyl-3-(p-trifluoromethylphenoxy)-3-phenyl-propylamine and its acid addition salts by (i) converting 3-chlorine-1-phenyl-propane-1-ol and/or 3-bromine-1-phenyl-propane-1-ol with methylamine to 3-me...
|
|
WO1999064034A9 |
The present invention is directed to multibinding compounds which are beta 2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/034210A1 |
Process for the preparation of chiral compounds of formula (I) comprising contacting a compound of formula (II) with a source of hydrogen or halide; wherein A is a chiral centre; X is selected from oxygen, sulphur and nitrogen; n is sele...
|
|
WO/2000/032553A1 |
The invention relates to a method for purifying triethanolamine which is produced by reacting aqueous ammonia with ethylene oxide in the liquid phase under pressure and at an increased temperature. To this end, excess ammonia, water and ...
|
|
WO/2000/032555A1 |
Methods of preparing and compositions comprising, derivatives of (+)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depre...
|
|
WO/2000/032554A1 |
A process for preparing a substantially single enantiomer of tramadol, or a pharmaceutically-acceptable salt thereof, proceeds by means of a classical salt resolution using a substantially single enantiomer of $i(o,o)-di-$i(p)-toluoyltar...
|
|
WO/2000/029357A1 |
The invention relates to a method for the racemization of optically active amines by reacting an optically active amine in the presence of hydrogen with a hydrogenation or dehydrogenation catalyst at an elevated temperature, wherein said...
|
|
WO/2000/027798A1 |
Disclosed is a process for the production of 2-amino-2-[2-(4-C¿2-20?-alkyl-phenyl)ethyl]propane-1,3-diol
s.
|
|
WO/2000/027799A1 |
New esters derived from substituted phenyl-cyclohexyl compounds, derived from tramadol, process for obtaining such esters and use of said compounds for the fabrication of a medicament having analgesic properties. These new products havin...
|
|
WO/2000/027797A1 |
Disclosed herein is a process for producing alkanolamines from the reaction between a polyolefin epoxide and an organic amino compound under conditions of elevated temperature and pressure, in the presence of a catalytic amount of an alc...
|
|
WO/2000/027796A1 |
The invention concerns a method for preparing tris(ether-amines) of formula (I): N[A-O-(B-O)¿n?-R]¿3? wherein R, A, B and n are as defined in Claim 1, comprising the reaction, in liquid phase, of an alkylene-glycol monoether of formula...
|
|
WO1999064038A9 |
Novel multibinding compounds are disclosed. The compounds of the invention comprise from 2-10 ligands covalently connected, each of said ligands being capable of binding to an nAChR receptor, thereby modulating the biological processes/f...
|
|
WO1999064031A9 |
The present invention is directed to multibinding compounds which are beta 2-adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis, and the like. They are...
|
|
WO/2000/024697A1 |
Aldehyde derivatives of polyethylene glycols and methods of making thereof are disclosed. These aldehyde derivatives can be used to make polyethylene glycol-hydrazines, polyethylene glycol-thiols, polyethylene glycol amines, and branched...
|
|
WO/2000/023414A2 |
A process for the preparation of optically active cyclohexylglycolate esters is described. The process utilizes carboxylic acid activation to couple $i((R))- or $i((S))-cyclohexylphenylglycolic acid (CHPGA) with 4-$i(N,N)-diethylamino bu...
|
|
WO1999063933A9 |
Disclosed are multibinding compounds which are agonists, partial agonists, inverse agonists, partial inverse agonist or antagonists of the GABA receptors, which are involved in neurological disorders. The multibinding compounds of this i...
|
|
WO1999064000A9 |
Novel multi-binding compounds (agents) which bind neurokinin receptors are used to treat disorders in mammals that are mediated by the neurokinin receptors, such as Parkinson's disease, Alzheimer's disease, depression, anxiety, inflammat...
|
|
WO/2000/021910A2 |
Compounds of Formula (I), wherein the substituents are as described in the specification or pharmaceutically acceptable salts or stereochemically isomeric forms thereof, useful for treating diseases related to calcium imbalance and metab...
|
|
WO/2000/021487A2 |
A method is disclosed for the preparation of optically pure isomers of formoterol and polymorphs of the novel $i(L)-tartrate salt of $i(R,R)-formoterol. Pharmaceutical compositions of the polymorphs and salts are also described.
|
|
WO/2000/018724A1 |
The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, ...
|
|
WO/2000/018722A2 |
The present invention relates to new derivatives of 6-(4-phenylbutoxy)hexylamine having the general formula (I) wherein R¿1? is CHO, or CHOR¿3?OR¿4?, wherein R¿3? and R¿4? are independently C¿1?-C¿6? alkyl, aralkyl or can form cyc...
|
|
WO/2000/018721A1 |
The invention relates to substituted polycyclic aryl and heteroaryl $i(tertiary)-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions an...
|
|
WO/2000/015614A1 |
The invention relates to novel pyridyl derivatives (I), their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
|
|
WO1999063983A9 |
Disclosed are novel multi-binding compounds (agents) which bind to PPAR gamma receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors thereby modulating the biological processes...
|
|
WO/2000/015600A2 |
The present invention relates to a process of making 2-amino-1,3-propanediol by reacting 1,3-dihydroxyacetone dimer with an amine compound.
|
|
WO/2000/015601A1 |
Aliphatic primary alcohols, including aliphatic primary alcohols possessing one or more oxygen, nitrogen and/or phosphorus heteroatoms that may be atoms substituting for carbon atoms in the alkyl group or component atoms of substituents ...
|
|
WO/2000/014096A1 |
The present invention relates to novel chiral 1,1' ferrocylene diphosphonites and the synthesis thereof, in addition to complexes of said compounds with metals from groups VIIb, VIIIb and Ib of the periodic table and to the use thereof f...
|
|
WO/2000/012461A1 |
This invention relates to a process for preparing 2-amino-5-cyanophenol.
|
|
WO1999042460A9 |
A process for the production of optically enriched (R)- or (S)-albuterol or (R)- or (S)-albuterol salts by the resolution of a novel ketal derivative 2-(N-t-butylamino)-1-(+2,2-dimethyl-1,2-benzodioxin-6-yl) ethanol, with a chiral tartar...
|
|
WO/2000/011203A1 |
The invention relates to a method for the racemic cleavage of alkoxy-substituted primary amines by reaction with an ester in the presence of a lipase and subsequent separation of the resulting optically active amide from the optically ac...
|
|
WO/2000/009463A1 |
The present invention relates to a process for stereoselective or regioselective chemical synthesis which generally comprises reacting a nucleophile, selected from the group consisting of water, alcohols, carboxylic acids, and thiols, an...
|
|
WO/2000/009517A2 |
This invention is directed to an improved process for the preparation of N-(phosphonomethyl)glycine (i.e., 'glyphosate'), a salt of N-(phosphonomethyl)glycine, or an ester of N-(phosphonomethyl)glycine. The process comprises combining an...
|
|
WO/2000/009475A1 |
Amine derivatives represented by general formula (1) or their salts, wherein R?1¿ represents C¿1-4? alkyl; R?2¿ represents (i), or (ii), (iii); R?3¿ represents C¿1-3? alkyl, hydroxylated C¿1-5? alkyl, C¿1-5? acyl, C¿2-5? alkenyl ...
|
|
WO/2000/007709A1 |
The present invention relates to surfactants useful in life science and industrial formulations. More particularly, the invention relates to surfactants of alkoxylated amine neutralized by aromatic sulfonic acid and pesticide formulation...
|
|
WO/2000/007976A1 |
A synthesis of fluoxetine is disclosed. The process begins with benzoylacetonitrile, which is reduced, optionally in the presence of a chiral ligand, to produce the corresponding aminoalcohol, and the amine is carbamoylated without isola...
|
|
WO/2000/007977A1 |
The invention relates to novel phenylethylamine derivatives, to a method for the production thereof and to their use as medicaments. The inventive phenylethylamines correspond to general formula (1).
|
|
WO/2000/006531A2 |
Nitric acid esters and nitrate salts with medicines active in the respiratory system pathology treatment.
|
